Quantum Biopharma (NASDAQ:QNTM) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Quantum Biopharma (NASDAQ:QNTM) from a sell rating to a strong sell rating in a research report released on Saturday morning.

Separately, Weiss Ratings downgraded Quantum Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, May 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has a consensus rating of “Sell”.

Quantum Biopharma Stock Down 3.9%

QNTM opened at $3.24 on Friday. The company’s 50-day moving average price is $4.77 and its 200 day moving average price is $4.61. Quantum Biopharma has a fifty-two week low of $2.07 and a fifty-two week high of $31.91. The firm has a market cap of $20.74 million, a price-to-earnings ratio of -0.39 and a beta of 0.43.

Institutional Trading of Quantum Biopharma

Large investors have recently modified their holdings of the company. Virtu Financial LLC bought a new stake in Quantum Biopharma in the 4th quarter valued at about $76,000. Jane Street Group LLC bought a new position in Quantum Biopharma in the 4th quarter worth about $80,000. Finally, Platform Technology Partners bought a new position in Quantum Biopharma in the 1st quarter worth about $199,000. Institutional investors and hedge funds own 1.24% of the company’s stock.

About Quantum Biopharma

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.